PH12022550117A1 - Oral formulations of edaravone and method of manufacturing thereof - Google Patents

Oral formulations of edaravone and method of manufacturing thereof

Info

Publication number
PH12022550117A1
PH12022550117A1 PH1/2022/550117A PH12022550117A PH12022550117A1 PH 12022550117 A1 PH12022550117 A1 PH 12022550117A1 PH 12022550117 A PH12022550117 A PH 12022550117A PH 12022550117 A1 PH12022550117 A1 PH 12022550117A1
Authority
PH
Philippines
Prior art keywords
edaravone
dosage form
present
compliant
manufacturing
Prior art date
Application number
PH1/2022/550117A
Other languages
English (en)
Inventor
Manappa Badiger Aravind
Naginbhai Patel Bhavesh
Mahendrabhai Shah Dharmesh
Atulkumar Shah Jigar
Dilipbhai Trivedi Madhavkumar
Purshottambhai Patil Mayurkumar
Natvarlal Jadav Nirav
Ashwinbhai Vora Pratik
Ketanbhai Choksi Rakshit
Jayantilal Thakkar Vishal
Original Assignee
Bdr Pharmaceuticals International Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bdr Pharmaceuticals International Private Ltd filed Critical Bdr Pharmaceuticals International Private Ltd
Publication of PH12022550117A1 publication Critical patent/PH12022550117A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH1/2022/550117A 2019-07-18 2020-07-17 Oral formulations of edaravone and method of manufacturing thereof PH12022550117A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921028874A IN201921028874A (cg-RX-API-DMAC7.html) 2019-07-18 2019-07-18
PCT/IN2020/050614 WO2021009775A1 (en) 2019-07-18 2020-07-17 Oral formulations of edaravone and method of manufacturing thereof

Publications (1)

Publication Number Publication Date
PH12022550117A1 true PH12022550117A1 (en) 2022-12-19

Family

ID=74210260

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550117A PH12022550117A1 (en) 2019-07-18 2020-07-17 Oral formulations of edaravone and method of manufacturing thereof

Country Status (9)

Country Link
US (1) US12691099B2 (cg-RX-API-DMAC7.html)
EP (1) EP3989968A4 (cg-RX-API-DMAC7.html)
BR (1) BR112022000914A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022000118A1 (cg-RX-API-DMAC7.html)
IN (1) IN201921028874A (cg-RX-API-DMAC7.html)
MX (1) MX2022000762A (cg-RX-API-DMAC7.html)
PH (1) PH12022550117A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021009775A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201541B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008197A2 (pt) 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
JP2025530029A (ja) * 2022-08-18 2025-09-10 ビーディーアール ファーマシューティカルズ インターナショナル プライベート リミテッド エダラボンの経口製剤およびその改良された製造方法
WO2024172852A1 (en) 2023-02-16 2024-08-22 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone
WO2026028170A1 (en) * 2024-08-02 2026-02-05 Lupin Limited Pharmaceutical composition of edaravone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE473214C (de) 1925-10-22 1929-12-04 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von 1-Phenyl-3-methyl-5-pyrazolon
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
CN1440749A (zh) * 2003-03-24 2003-09-10 南昌弘益科技有限公司 易达拉封注射剂及其制备工艺——治疗急性脑梗塞
CN1241565C (zh) 2003-04-16 2006-02-15 浙江震元制药有限公司 依达拉奉药物组合物及制备
WO2009067343A1 (en) 2007-11-21 2009-05-28 Teikoku Pharma Usa, Inc. Pyrazolone derivative emulsion formulations
CN101953832B (zh) 2010-08-10 2012-02-15 南京师范大学 β-环糊精包合依达拉奉的口服药物组合物及其制备方法
CN102349893A (zh) * 2011-08-19 2012-02-15 福建天泉药业股份有限公司 依达拉奉药物组合物
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
CN109125261B (zh) 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
CN107773545A (zh) * 2016-08-29 2018-03-09 烟台益诺依生物医药科技有限公司 依达拉奉与(+)‑2‑莰醇的舌下用药物组合物
EP3785703A1 (en) 2017-01-17 2021-03-03 Treeway TW001 B.V. Treatment comprising oral or gastric administration of edaravone
BR112019014712A2 (pt) 2017-01-17 2020-02-18 Treeway Tw001 B.V. Tratamento médio que compreende a administração entérica de edaravona
RU2693627C2 (ru) * 2017-11-03 2019-07-03 Общество С Ограниченной Ответственностью "Валента - Интеллект" Комбинации эдаравона для лечения ишемических повреждений мозга
WO2019213333A1 (en) * 2018-05-04 2019-11-07 Carnot2, Llc Combination therapies with edaravone and prodrugs of edaravone that are orally bioavailable and have altered pharmacokinetic properties
BR112021008197A2 (pt) * 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral

Also Published As

Publication number Publication date
US20220409588A1 (en) 2022-12-29
US12691099B2 (en) 2026-07-28
EP3989968A4 (en) 2023-07-12
MX2022000762A (es) 2022-04-01
ZA202201541B (en) 2023-05-31
CL2022000118A1 (es) 2023-03-10
EP3989968A1 (en) 2022-05-04
IN201921028874A (cg-RX-API-DMAC7.html) 2021-01-22
BR112022000914A2 (pt) 2022-03-08
WO2021009775A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
PH12020550341A1 (en) Niraparib formulations
WO2018198077A3 (en) 6-6 FUSIONED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS INHIBITORS OF LATS
MX361488B (es) Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk).
MX2019011491A (es) Formulaciones de niraparib.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
EA201201294A1 (ru) Гидрат гидрохлорида агомелатина и его получение
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX383551B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida
MY191352A (en) Aldosterone synthase inhibitors
MX2022000762A (es) Formulaciones orales de edaravone y metodo de fabricacion de las mismas.
MX380037B (es) Antagonistas novedosos 5-ht2
MY160337A (en) Agomelatine hydrobromide hydrate and preparation thereof
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
MX2025001437A (es) Formulaciones orales de acetato de abiraterona y metodo de fabricacion de las mismas
MX2021012200A (es) Adyuvante soluble en agua y composición que contiene el mismo.
MX370974B (es) Preparación de citrato de zinc y composiciones para cuidado oral que contienen citrato de zinc.
CA2928305C (en) A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
ZA202309924B (en) Amarouciaxanthin a esters and uses thereof
MX2023008883A (es) Polimorfo de diclorhidrato de latrepirdina.
ZA202200227B (en) Stable oral composition of cyclophosphamide